Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gene Colice

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
The Lancet. Respiratory Medicine|January 26, 2023
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension studyAndrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 24, 2023
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)Ian D Pavord, Flavia C L Hoyte, Andrew W Lindsley, et al.
Annals of the American Thoracic Society|March 11, 2015
Increased Dose of Inhaled Corticosteroid versus Add-On Long-acting β-Agonist for Step-Up Therapy in AsthmaElliot Israel, Nicolas Roche, Richard J Martin, et al.
American Journal of Respiratory and Critical Care Medicine|April 4, 2023
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical TrialsJonathan Corren, Andrew Menzies-Gow, Geoffrey Chupp, et al.
The Lancet. Respiratory Medicine|May 26, 2018
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trialRichard J Russell, Latifa Chachi, J Mark FitzGerald, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
The Lancet. Respiratory Medicine|January 26, 2023
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension studyAndrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 24, 2023
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)Ian D Pavord, Flavia C L Hoyte, Andrew W Lindsley, et al.
Annals of the American Thoracic Society|March 11, 2015
Increased Dose of Inhaled Corticosteroid versus Add-On Long-acting β-Agonist for Step-Up Therapy in AsthmaElliot Israel, Nicolas Roche, Richard J Martin, et al.
American Journal of Respiratory and Critical Care Medicine|April 4, 2023
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical TrialsJonathan Corren, Andrew Menzies-Gow, Geoffrey Chupp, et al.
The Lancet. Respiratory Medicine|May 26, 2018
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trialRichard J Russell, Latifa Chachi, J Mark FitzGerald, et al.
Pageof 7